Therapeutic Education in Parkinson's Disease: What Impact on Drug Representations of Patients? (ETPARK-REMED)

NCT04228523 | Completed

• 2 other identifiers: RC31/19/01832019-A02754-53
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

Dopaminergic drug can have adverse effects leading to potential serious consequences. Therapeutic patient education must promote the understanding of drugs to improve its management. This study tries to evaluate the effect of therapeutic education workshop on Parkinson disease's drug (drug workshop) on the evolution of drug's representations in patients with Parkinson's disease compared to a control group.

Conditions

Parkinson Disease

Keywords

Therapeutic education; Parkinson Disease; Socials representations

Outcome Measures

Primary Outcomes (2)

• Evolution of Drug representation in Patients : BMQ

  Evolution of Drug representation through the Believe about Medicines Questionnaire (BMQ) compared to the control group. Evolution will be compared between the Baseline and the end of the study BMQ with eighteen items coded from 1 " "strongly agree" to 5 "strongly disagree".

  Three months

• Evolution of Drug representation in Patients : Verbal association

  Evolution of Drug representation through verbal association tasks compared to the control group. Evolution will be compared between the Baseline and the end of the study

  Three months

Secondary Outcomes (5)

• Drug representation in caregivers : Verbal association

  Day 1

• Drug representation in caregivers : BMQ

  Day 1

• Knowledge about the disease

  three months

• Evolution in life quality : VAS

  three months

• Evolution in life quality : PDQ-(39)

  three months

Study Arms (2)

Therapeutic education workshop

EXPERIMENTAL

Two group receive therapeutic education workshop already existing in Toulouse University Hospital

Other: Therapeutic education workshop

Speaking Therapy

OTHER

One group receive speaking therapy already existing in Toulouse University Hospital

Other: Speaking Therapy

Interventions

Therapeutic education workshop OTHER

Workshop on Parkinson disease drug has several educative sequences (lasting 4hours). * A first round table is organized to know the needs and issues related to drug management of patients. * The 1st educative sequence consists in knowing the different class of dopaminergic drugs and their action. * The 2nd educative sequence leads patients to understand their prescription and be aware of the needs to take pills regularly. * The 3rd educative sequence consists in learning and identifying potentials adverse effects and finds effective strategies to prevent them. At the end, one patient explains its tips and tricks about its drug management

Therapeutic education workshop

Speaking Therapy OTHER

Speaking group is leaded by a psychologist from Centre Expert Parkinson (lasting 2 hours). This specific time is an exchange between patients with Parkinson disease who feel free to come. It is about sharing its own experience. It is a very special moment, confidential and kindly where patients don't judge themselves and speak only if they want to.

Speaking Therapy

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with Parkinson's disease according to the United Kingdom Parkinson Disease Society Brain Bank (UKPDSBB) criteria,
• Patients who are already in therapeutic education program ETPARK,
• Patients who need and want to participate in therapeutic education workshop on Parkinson disease drug,
• Patients with health insurance,
• Patients who have signed a written informed consent form.

You may not qualify if:

• Patients suffering from another parkinsonian syndrome (multiple system atrophy, progressive supranuclear palsy etc.),
• Patients who has already done workshop on Parkinson disease drug (program ETPARK)
• Patients already included in clinical trial during the study,
• Patients who have severe psychiatric disorders or dopaminergic psychosis,
• Patients with cognitive impairment,
• Patients unable to complete the various scales used in the study,
• Patients under juridical protection,
• Women pregnant or breastfeeding.

Sponsors & Collaborators

• University Hospital, Toulouse: lead
• France Parkinson Association: collaborator

Study Sites (1)

Toulouse University Hospital

Toulouse, Occitanie, 31059, France

Location

Related Publications (1)

• Faurie I, Harroch E, Scotto d'Apollonia C, Corte S, Arcari C, Mohara C, Barthelemy C, Fabre MH, Boussac M, Damase-Michel C, Almudever B, Croity-Belz S, Brefel-Courbon C. Impact of therapeutic education on the evolution of social representations of medication in patients with Parkinson's disease: A quantitative and qualitative study (ETPARK REMED). Rev Neurol (Paris). 2023 Dec;179(10):1086-1094. doi: 10.1016/j.neurol.2023.03.026. Epub 2023 Aug 24.

  PMID: 37633737 RESULT

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Study Officials

• Christine Brefel-Courbon, MD

  Univeristy Hospital Toulouse

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: therapeutic education or speaking group

Study Record Dates

• First Submitted: January 9, 2020
• First Posted: January 14, 2020
• Study Start: February 24, 2020
• Primary Completion: January 1, 2021
• Study Completion: January 1, 2021
• Last Updated: May 6, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)